The page provides information about products from Otsuka Pharmaceutical’s healthcare business.

This is the page for information for healthcare professionals on Otsuka Pharmaceutical’s website.

Otsuka Pharmaceutical’s comprehensive efforts to create a society where people with dementia and those without it can live life on their own terms.

Create things that resonate around the world without imitation. This is the Medical-Related Business page of Otsuka Pharmaceutical.

Otsuka Pharmaceutical’s official account shares health-related information and initiatives, along with employees’ thoughts and stories.

Otsuka Pharmaceutical’s page explains topics about health and illness in an easy-to-understand way. It describes its aim to help patients recover and contribute to people’s health.

Launched in 2026, /zeroz is a self-conditioning food containing the plant-derived ingredient kaempferol. It supports daily well-being by working with the body’s natural capabilities.

Otsuka Pharmaceutical’s “Recruiting Team Presents” series shares employees’ experiences with job seekers. This page introduces Takeuchi’s career in the NC Business Division’s Mass Retail Department.

View announcements from Otsuka Pharmaceutical.

This is Otsuka Pharmaceutical’s Sustainability page on “Career Autonomy Support.”

The company’s document screening for mid-career and disability employment applications may take some time.

Hear from Otsuka Pharmaceutical employees.

Otsuka Pharmaceutical corporate information: List of Executives.

Otsuka Pharmaceutical corporate information.

This is the page about Otsuka Pharmaceutical’s research and development “Global Satellite System.”

This is Otsuka Pharmaceutical’s Philosophy page.

Otsuka Pharmaceutical’s research and development.

This is the “Contact” page on Otsuka Pharmaceutical’s website.

This is the “Partnering and Licensing Activities” page on Otsuka Pharmaceutical’s website.

Otsuka Pharmaceutical is a total healthcare company that contributes to the health of people around the world through its two core businesses: Medical-Related Business and Nutraceuticals-Related Business.

Otsuka Pharmaceutical announces Phase 3 FUSION results for ulefnersen, a potential targeted treatment for the FUS-ALS community.

Sep 2026 · Otsuka Pharmaceutical Co., Ltd.News article

Otsuka Pharmaceutical and Jolly Good launch new content for FACEDUO dementia care support VR, titled “Understanding a New Perspective on Dementia.”

Sep 2026 · Otsuka Pharmaceutical Co., Ltd.News article

Otsuka Pharmaceutical presents new Phase 3b results for SIMTRIYO® (centanafadine), highlighting consistent improvements across ADHD symptoms, anxiety, and associated features. The findings concern adults with ADHD and comorbid anxiety.

Sep 2026 · Otsuka Pharmaceutical Co., Ltd.News article

Otsuka Pharmaceutical Co., Ltd News Releases

Aug 2026 · Otsuka Pharmaceutical Co., Ltd.News article